TCM related concept stocks continue to rise, and the industry suggests appropriate participation

[pharmaceutical network pharmaceutical stock market] recently, traditional Chinese medicine related concept stocks have continued to rise, causing widespread concern among investors Tonghuashun data shows that from February 3 to February 6, the Chinese medicine sector rose 10.59% Among them, in recent trading days, HongRi Pharmaceutical Co., Ltd., Harbin Pharmaceutical Co., Ltd., Xinghu science and Technology Co., Ltd and many other proprietary Chinese medicine stocks rose continuously In the morning of February 6, HongRi pharmaceutical rose 6.03% to 5.45 yuan, with a turnover of 191.8 million yuan, a turnover rate of 1.51%, an amplitude of 9.53%, and a volume ratio of 5.13 According to the third quarter report of HongRi pharmaceutical in 2019, the company has realized an operating revenue of 3.602 billion yuan, a net profit of 516 million yuan, a per share income of 0.17 yuan and a P / E ratio of 58.56 According to the public information, the main business of the company is the research and development, production and sales of drugs and medical devices On February 6, Harbin Pharmaceutical Co., Ltd increased by 5% at the opening As of 9:26, it was at 5.91 yuan, with a turnover rate of 0.31% On the evening of June 6, Harbin Pharmaceutical Co., Ltd announced that its current P / E ratio is significantly higher than the industry level By the end of February 6, 2020, the company's rolling P / E ratio is 138.55 times, and the rolling P / E ratio of the same industry is 38.54 times In addition, the trading market shows that from February 3 to February 6, Harbin Pharmaceutical Co., Ltd has harvested four trading plates in a row, with the cumulative increase of 46.67% in these four trading days According to the announcement of 2019 annual performance reduction disclosed by Harbin Pharmaceutical Co., Ltd., after preliminary calculation by the financial department, the company expects that the net profit attributable to the shareholders of the listed company in 2019 will be reduced by 27 million yuan to 31 million yuan, 78% to 31 million yuan, compared with the same period of last year 90%; compared with the same period of last year, the net profit attributable to the shareholders of the listed company deducting non recurring profit and loss will be reduced by 25 million yuan to 295 million yuan, 104% to 121% year-on-year
According to the data, Harbin Pharmaceutical Co., Ltd is a comprehensive pharmaceutical enterprise Its products focus on the fields of anti infection, cardio cerebrovascular, cold medicine, digestive system, anti-tumor medicine and nutritional supplements, involving more than 20 dosage forms and more than 700 product specifications, mainly including amoxicillin capsule, Pediatric Paracetamol Huang Namin granules, cefotiam hydrochloride for injection, Salvia miltiorrhiza for injection and Qianlie DIL injection, calcium gluconate oral solution, zinc gluconate oral solution and other products On February 5, Xinghu science and technology opened up 5% higher As of 9:30, it was 6.5 yuan, with a turnover of 1.98% and a turnover of 83.4882 million yuan On the evening of February 5, Xinghu technology announced that the deviation value of closing price rise of the company's shares in three consecutive trading days had reached more than 20% again In recent years, the proportion of ribavirin API in the company's operating revenue is very small, which has little impact on the company's overall operating performance The company expects that the net profit attributable to the shareholders of the listed company from January to December 2019 will be 135-160 million yuan, an increase of 219% - 278% compared with the same period of last year According to the data, Xinghu technology is a manufacturing enterprise with biological fermentation and biochemical as the core technology, mainly engaged in the R & D, production and sales of food additives, feed additives, chemical APIs, pharmaceutical intermediates, and the product application covers food processing, feed processing, pharmaceutical manufacturing and other fields Relevant securities people think that they can properly participate in the recent continuous rise of pharmaceutical stocks, but in the long run, "good track" and performance are the hard strength of pharmaceutical stocks.